GLP-1 Receptor Agonist Gastrointestinal Injury Litigation

In litigation Mass-tort payouts ($50k+) mass_tort · pharma

GLP-1 (Ozempic, Mounjaro) gastrointestinal injury MDL 3094 - active intake, bellwether selection underway

Eligibility hint

Took Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound and were diagnosed with gastroparesis, severe bowel obstruction, or pancreatitis

Estimated payout range

$50,000 – $1,500,000

MDL filed

2024-02-02

Current score

0.85 / 1.00

Official source

View source →

MDL No. 3094 in the Eastern District of Pennsylvania consolidates claims that GLP-1 receptor agonists (semaglutide and tirzepatide) caused gastroparesis, pancreatitis, and bowel obstruction. Sodhi et al. (JAMA, Oct 2023) found about 9x higher pancreatitis rate, 4x bowel obstruction, and 3.7x gastroparesis vs comparator drug. FDA added ileus warning to the Ozempic label in September 2023. MDL covers Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound). Bellwether trials anticipated 2027.

Recent signals

CL filing: HERRERRA v. ELI LILLY AND COMPANY courtlistener_search · 2026-07-18
CL filing: BEACHNER v. NOVO NORDISK A/S courtlistener_search · 2026-07-18
South Africa's iDexis appeals court ruling over compounded weight-loss drugs - Reuters google_news · 2026-07-18
Research Links Ozempic to Vision Loss as GLP-1 Lawsuits Increase - The Legal Examiner google_news · 2026-07-18
CL filing: MILLWOOD v. NOVO NORDISK A/S courtlistener_search · 2026-07-17
Link Between NAION and Ozempic, Wegovy Will Be Focus of Early Discovery in GLP-1 Vision Loss Lawsuits - AboutLawsuits.com google_news · 2026-07-17
CL filing: GENOVESI v. NOVO NORDISK INC. courtlistener_search · 2026-07-16
CL filing: WALKER v. NOVO NORDISK INC courtlistener_search · 2026-07-16
CL filing: Hill v. NORDISK INC. courtlistener_search · 2026-07-16
CL filing: PETERS v. NOVO NORDISK INC. courtlistener_search · 2026-07-15

Brands: novo nordiskeli lilly
Products: ozempicwegovyrybelsusmounjarozepboundsemaglutidetirzepatideglp-1gastroparesis

Frequently asked questions

Who qualifies for the GLP-1 Receptor Agonist Gastrointestinal Injury Litigation case?

You may qualify if the following applies to you: Took Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound and were diagnosed with gastroparesis, severe bowel obstruction, or pancreatitis. Eligibility criteria can change as the case develops.

How much could a GLP-1 Receptor Agonist Gastrointestinal Injury Litigation claim be worth?

Estimated payouts range from $50,000 to $1,500,000 depending on individual circumstances. These are estimates based on comparable outcomes, not guarantees.

What is the current status of the GLP-1 Receptor Agonist Gastrointestinal Injury Litigation case?

In litigation. MDL No. 3094 in the Eastern District of Pennsylvania consolidates claims that GLP-1 receptor agonists (semaglutide and tirzepatide) caused gastroparesis, pancreatitis, and bowel obstruction. Sodhi et al. (JAMA, Oct 2023) found about 9x higher pancreatitis rate, 4x bowel obstruction, and 3.7x gastroparesis vs comparator drug. FDA added ileus warning to the Ozempic label in September 2023. MDL covers Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound). Bellwether trials anticipated 2027.

How do I check whether I'm included?

Take the free 30-second audit at https://getclaimscout.com/audit and claimscout matches the brands and products you've used against every active class action settlements and mass torts it tracks, or review the eligibility details at https://getclaimscout.com/matters/ozempic-stomach-paralysis.

Think this might apply to you?
Take a 30-second audit and we'll match every brand you've used against active settlements.

Start audit →

Building an AI agent? This matter is available as JSON at https://getclaimscout.com/api/v1/matters/ozempic-stomach-paralysis, and the full registry is at /api/v1/matters. Agent quickstart: /llms.txt. Schema: /openapi.json.